Hemophilia A: Symptoms, Factor VIII and Treatment

This guide explains the questions that matter in hemophilia A: what a factor VIII result means, how treatment choices differ, and what changes when inhibitors, procedures or unexpected bleeding enter the picture.

When bleeding needs urgent help

Seek emergency medical help after a head or neck injury, or for a sudden severe headache, confusion, weakness, a seizure, difficulty breathing or swallowing, major trauma, vomiting blood, or black or bloody stools. Follow your established emergency plan and use your local emergency number when needed. Internal bleeding may be serious before a large bruise appears. Do not wait for a routine appointment or for symptoms to become unmistakable. ⁷

Tell emergency staff immediately that you have hemophilia A. Suspected serious bleeding may need treatment before imaging or other investigations are completed; the emergency team should coordinate with your hemophilia service without delaying necessary care. ⁶

What is hemophilia A?

Hemophilia A is a problem with the activity of clotting factor VIII, a protein that helps clotting proteins work together. It is a cofactor, rather than a digestive enzyme or a blood thickener. Too little effective factor VIII makes the clotting response less reliable. Bleeding may continue longer than expected or restart after initially appearing to stop, including inside tissues where it cannot easily be seen. ²⁰

The missing clotting protein matters because treatment must match the disorder. Hemophilia A involves factor VIII; hemophilia B involves factor IX. Their bleeding symptoms can look alike, so symptoms alone cannot distinguish them. Giving the diagnosis its full name helps prevent confusion when discussing test results, medicines or an emergency plan with a clinician who does not know your history. ¹⁵

Congenital hemophilia A is associated with a change in the F8 gene that affects factor VIII production or function. The diagnosis concerns how well this part of coagulation works, not whether blood is visibly thin. A different disorder, acquired hemophilia A, involves antibodies against the person’s own factor VIII and is discussed separately below. Identifying the underlying disorder makes the factor result clinically meaningful. ¹

Factor VIII levels and the bleeding pattern

Baseline factor VIII activity is commonly described as severe below 1%, moderate from 1% through 5%, and mild above 5% but below 40%. Percent activity describes function relative to a laboratory reference. These categories refer to the underlying level, interpreted with the testing circumstances in mind. A result after replacement treatment is not interchangeable with the untreated baseline. The categories are not stages that everyone passes through as they get older. ¹

The laboratory category gives useful context, but the bleeding history adds information it cannot supply. Severe disease can cause spontaneous bleeding, especially in joints and muscles, while milder disease may become apparent after a substantial injury, surgery or dental treatment. Two people in the same category need not have identical experiences. The site, frequency and circumstances of bleeding help the specialist understand the person’s actual bleeding pattern, sometimes called the phenotype. ²¹

For example, unusual bruising may become noticeable when a young child starts moving around independently. Another person may reach adulthood before bleeding after a procedure prompts factor testing. These are illustrative possibilities, not a timetable for diagnosis. Years without a major bleed do not prove normal clotting, particularly if there has been little exposure to surgery or significant injury. Likewise, a mild classification does not make every future procedure low risk. The medical history should include prolonged bleeding after past procedures, even if no diagnosis was made at the time. ²¹

Joint and muscle symptoms deserve attention

Contact your hemophilia team promptly for new joint pain, swelling or a feeling that movement is becoming restricted, and for suspected muscle bleeding or blood in the urine. A symptom can matter even when there is no obvious injury. Describe where the problem is, when it began and whether it is worsening. If you cannot reach the team and symptoms are concerning, seek urgent medical assessment rather than waiting for the next scheduled review. Emergency symptoms require emergency care even if you are already receiving preventive treatment. Blood in the urine is also a reason for advice about the cause and appropriate treatment, rather than automatically using an oral-bleeding medicine. ⁷

Bleeding into a joint is called hemarthrosis. Pain, warmth, swelling and reduced movement can occur, but these findings do not identify the cause by themselves. In someone with hemophilia, a new painful joint needs timely assessment; an apparently familiar symptom should not automatically be assigned to an old joint problem. Examination and, when appropriate, imaging help distinguish bleeding from other causes and guide the next step. ²³

A deep muscle bleed may have no visible bruise

Bleeding in a deep muscle near the hip, such as the iliopsoas, may cause pain in the lower back, groin or hip. The person may keep the hip bent, have difficulty straightening it, or notice altered sensation in the thigh. The skin can look normal because the blood is collecting deeper inside. These symptoms warrant urgent professional assessment. Do not try to prove the diagnosis by stretching the leg, pressing deeply into the painful area or waiting for a bruise to appear. ¹⁸

Inheritance and family testing

The F8 gene is on the X chromosome. In the usual inheritance pattern, a mother with one changed F8 copy has a 50% chance of passing that copy to each child. Each pregnancy is an independent event; a previous child’s result does not change the next child’s probability. Sons who inherit the changed copy generally have hemophilia. Daughters who inherit it may also have reduced factor levels or bleeding symptoms, so the word carrier does not settle their clinical needs. ¹²

A father with an F8 variant passes his X chromosome to his daughters and his Y chromosome to his sons. He therefore does not transmit that X-linked variant directly to a son. Hemophilia can also appear in a family without an already recognized affected relative. Genetic counseling can explain the particular family’s findings and available testing without assuming which reproductive choices a person should make. Testing relatives should follow the identified family findings and specialist advice. ¹²

Once a family’s F8 variant is identified, targeted genetic testing can clarify who inherited it. Factor activity and genetic testing answer different questions: one measures clotting function at testing, while the other looks for an inherited variant. ¹

Women and girls can need hemophilia care

Women and girls with an F8 variant need attention to their own bleeding, not only discussion of what a future child might inherit. Heavy periods, prolonged bleeding after dental work, easy bruising or excessive bleeding during a procedure are reasons to seek assessment. A factor level helps define the immediate clinical picture. It should be considered alongside symptoms and family history rather than used to dismiss a person’s account of bleeding that disrupts school, work or everyday activities. ⁸

Factor VIII activity can change with hormones, pregnancy and age. A result obtained years earlier may therefore not answer every question about an upcoming operation or pregnancy. Ask the specialist when reassessment is appropriate, including before menstruation begins in an at-risk child or before a planned procedure. Pregnancy and birth need coordinated individual planning. Being called a carrier is not a substitute for that assessment, and having a normal factor result does not by itself establish whether an F8 variant is present. The testing plan should cover both genetic questions and the bleeding risks relevant to the person’s present circumstances. ⁸

Pregnancy, postpartum bleeding and newborn assessment

Factor VIII often rises during pregnancy, which can obscure a previously unrecognized low baseline. After birth it falls again, so a reassuring pregnancy result does not remove the risk of heavy postpartum bleeding. Hematology and maternity teams should assess the mother’s bleeding needs together. The birth plan also considers a baby who may have inherited hemophilia, including ways to reduce delivery-related injury. Maternal clotting assessment and the baby’s possible diagnosis are related questions, but each needs its own clinical attention. ²⁸

Targeted testing soon after birth is appropriate when there is a known family risk or concerning bleeding; this is different from universal newborn screening for hemophilia. Cord blood may be used to measure clotting factors. If hemophilia is possible, obtain pediatric hematology advice before circumcision because bleeding can occur after the procedure. Routine preventive care still matters: hemophilia is not a reason to omit vitamin K at birth or routine vaccinations. The clinical team should arrange appropriate precautions for injections and blood sampling. ²⁸

How hemophilia A is diagnosed

Diagnosis starts with the pattern of bleeding, previous procedures, family history and current medicines. Initial blood tests may include a blood count and screening clotting tests, followed by specific factor activity measurements. A normal activated partial thromboplastin time, or aPTT, does not exclude mild hemophilia A. Conversely, an abnormal aPTT is not specific to hemophilia. The clinician and laboratory need to interpret the findings together rather than assigning a diagnosis from one screening result. ²

Low factor VIII also requires consideration of von Willebrand factor, which supports factor VIII in the circulation. Some forms of von Willebrand disease, including type 2N, can resemble hemophilia A. A mixing study may help investigate a prolonged clotting time, but it is only part of the workup. Anticoagulant medicines, inhibitors and sample-related problems can affect interpretation. Selected genetic or inhibitor testing may be needed to resolve the diagnosis or explain an unexpected result. These distinctions affect treatment: a low activity measurement is a finding to explain, not permission to select a factor product without completing the assessment. ²

Why emicizumab changes laboratory testing

Emicizumab can shorten or normalize aPTT and make an ordinary aPTT-based, one-stage factor VIII result misleadingly high. These tests cannot be read as evidence that the person’s factor VIII deficiency has disappeared or that important bleeding is excluded. Human-reagent chromogenic factor VIII assays also respond to emicizumab and can overestimate its hemostatic effect. Merely requesting a chromogenic assay is therefore insufficient: the laboratory needs to know which reagents are involved. ³

Bovine-reagent chromogenic assays are insensitive to emicizumab and can measure endogenous or infused factor VIII. A bovine-based chromogenic Bethesda assay can assess factor VIII inhibitors; a clot-based Bethesda result may be falsely negative. Tell clinicians and laboratories about emicizumab before blood tests or procedures, including after it has been stopped, because interference can persist for up to six months. An unfamiliar hospital needs this information before interpreting routine coagulation results. The assay choice should be documented alongside the result. ³

Factor VIII replacement: treating and preventing bleeding

Factor VIII replacement supplies the clotting protein that is missing or working inadequately. It is given into a vein and can be used to treat a bleed or as regular prevention. Those are different purposes, even when the same product is involved. An infusion given for one episode does not establish a permanent correction of the disorder. The care team selects the product and explains when to use it, what response to expect and when additional assessment is needed. ²²

Some people or caregivers learn to administer replacement at home after supervised teaching. Venous access, age, confidence and the practical demands of treatment influence what is workable. Training includes safe preparation and recognition of problems; this article is not an infusion manual. Difficulty using the prescribed treatment is worth discussing early, because an apparently suitable prescription is less useful if it cannot be delivered reliably in the person’s daily circumstances. ²²

Replacement products include recombinant factor VIII and products derived from human plasma. Products also differ in how long their activity lasts. A longer-acting option does not create the same duration of protection for every person, and the chosen regimen remains individualized. ²⁰

The treatment response needs to be understood over time. A factor level measured soon after an infusion describes that sampling point; it does not show that protection stays unchanged until the next treatment. Prevention and management of a new bleed remain separate parts of the plan. ²⁰

What a prevention plan should achieve

Prophylaxis means treatment intended to prevent bleeding, rather than waiting to treat each episode after it happens. The goal extends beyond fewer visible bruises: care should support joint health, movement and participation in ordinary life. A comprehensive hemophilia team brings together medical treatment, nursing education, physical assessment and support for the pressures of a long-term condition. The particular combination of services varies, but treatment decisions should take the person’s functioning as well as laboratory findings into account. ¹⁶

A useful review asks whether bleeding is occurring, whether a particular joint repeatedly causes trouble, and whether the plan fits the person’s activities and treatment burden. Children’s needs change as they grow; adults may face different work, mobility or health concerns. Preventive care is therefore an ongoing clinical process. A plan that worked previously may need reassessment when the bleeding pattern or daily demands change, even if the diagnosis itself is unchanged. ¹⁶

The need for prophylaxis is not determined by the severe laboratory category alone. Bleeding phenotype, joint health and individual circumstances matter, including in some people with moderate or mild baseline deficiency. ³

Desmopressin: an option for selected mild hemophilia A

Desmopressin, often called DDAVP, can help selected people with mild hemophilia A by increasing available factor VIII. A supervised challenge test establishes whether the person has a satisfactory and safe response. A diagnosis of mild disease alone does not show that DDAVP will work well enough. The team considers the rise in factor activity and how long protection is needed, rather than treating a response at one sampling point as sufficient for every future situation. ⁹

DDAVP is not adequate by itself for major bleeding. Age, other health conditions and the intended procedure influence suitability, and children need particular care. The plan should specify when this option is appropriate and when another form of hemostatic support is required. Do not substitute it for a prescribed emergency treatment because it seems easier to administer. A previous successful use does not settle suitability for a different procedure. ⁹

Repeated DDAVP use can produce a diminishing response, so it is not an unlimited substitute for replacement treatment. It is an option specific to suitable hemophilia A patients, not treatment for factor IX deficiency in hemophilia B. ¹⁵

DDAVP can retain water and cause dangerously low blood sodium, occasionally with seizures. Follow the care team’s individualized fluid restriction and monitoring instructions; there is no universal drinking allowance suitable for every patient. Ask for those instructions before treatment rather than guessing afterward. Persistent headache, unusual confusion, rapid weight gain or a seizure needs medical attention, with emergency help for severe symptoms. Tell the treating clinician that DDAVP was used so the possible effect on water balance is considered. If instructions are unclear, contact the prescribing team before use. ¹⁰

Emicizumab and breakthrough bleeding

Emicizumab mimics part of factor VIII’s clotting function and is used for prevention. It is not factor VIII replacement. Because it works differently, it can provide preventive protection even when antibodies inhibit factor VIII, but it does not make those antibodies disappear. ⁴

A person taking emicizumab still needs a specific plan for an injury, surgery or breakthrough bleed. The appropriate acute treatment depends partly on whether factor VIII inhibitors are present. People without inhibitors may need factor VIII replacement. For people with inhibitors, MASAC favors recombinant activated factor VII over activated prothrombin complex concentrate, or aPCC, for acute bleeding. These are specialist-selected pathways; the choice should already be clear in the emergency plan rather than improvised during a bleed. ⁶

Combining emicizumab with aPCC can cause dangerous clotting and thrombotic microangiopathy, a disorder affecting small blood vessels. Do not assume that an older rescue regimen is suitable after starting emicizumab. Unexpected bleeding or reduced protection should be assessed with the treatment center, while serious bleeding still requires urgent care. Preventive treatment does not remove the need to act on emergency symptoms. ⁶

Other nonfactor treatments: check the current local indication

Other preventive medicines act on natural restraints within coagulation: Alhemo and Hympavzi target tissue factor pathway inhibitor, while Qfitlia lowers antithrombin. These approaches have product-specific safety and breakthrough-bleed instructions. An existing rescue plan must be reviewed when treatment changes; medicines cannot be assumed interchangeable simply because each helps prevent bleeding. Alhemo and Hympavzi also carry warnings about thromboembolic events. ⁴

United States labeling checked on 16 October 2026 includes hemophilia A prophylaxis with Hemlibra from birth, Alhemo from age 12, Hympavzi from age 6, and Qfitlia from age 12, with or without factor VIII inhibitors. Qfitlia requires antithrombin-guided treatment and carries boxed warnings for thrombosis and gallbladder disease, plus liver monitoring. Eligibility alone does not establish which option is appropriate for an individual. ⁴

European Union indications differ. For hemophilia A, Alhemo is indicated from age 12 with inhibitors, or for severe disease without inhibitors. Hympavzi requires age 12 or older and weight of at least 35 kg, with inhibitors or severe disease without inhibitors. Hemlibra includes people with inhibitors and, without inhibitors, severe disease or moderate disease with a severe bleeding phenotype. These distinctions matter when reading treatment information written for another country; authorization also does not guarantee local supply or funding. ⁵

When factor VIII inhibitors change care

An inhibitor is an antibody that interferes with factor VIII treatment. It may be suspected when the expected response becomes inadequate, but symptoms alone cannot measure it. Laboratory testing and the treatment history help establish what is happening. The inhibitor titer, which describes its measured strength, is part of the assessment; the team also considers how it behaves with renewed factor exposure. A previously effective treatment may need a different strategy when an inhibitor is present. ¹³

Care then addresses several separate aims: controlling an active bleed, maintaining preventive protection and, when appropriate, attempting immune tolerance induction. Immune tolerance uses repeated factor exposure in an effort to teach the immune system to accept it. This is a specialist process with treatment burden and follow-up needs, not a guaranteed cure or a single protocol that suits everyone. Preventing bleeding while an inhibitor persists is different from demonstrating that the inhibitor has been eliminated. ¹³

A treatment record is clinically useful when the response changes. Note the suspected bleed, treatment given and subsequent symptoms according to the center’s instructions. Continuing pain or swelling despite treatment needs reassessment rather than an assumption that another identical episode is underway. Report treatment reactions and difficulty achieving the expected response promptly so the team can investigate. ¹⁸

Joint recovery, persistent pain and rehabilitation

A painful joint can reflect a new bleed, inflammation or another problem, so the same symptom may call for a different response on different occasions. Tell the clinician whether there is new swelling, warmth or loss of movement compared with your usual baseline. That comparison helps frame the examination without replacing it. ²³

Blood within a joint can provoke inflammation of its lining, called synovitis. Repeated bleeding and continuing inflammation can contribute to lasting joint damage, or hemophilic arthropathy. Stopping an acute bleed, settling inflammation and managing established damage are related but distinct goals. A preventive medicine can reduce future bleeding risk without reversing cartilage damage that is already present. Persistent pain therefore deserves assessment even when the person has had few recent recognized bleeds. ²⁵

Physiotherapy is coordinated with hemostatic care and the stage of recovery. Protecting an acutely affected joint is different from gradually restoring movement, strength and useful activity afterward. Progress depends on symptoms and function rather than a fixed calendar for everyone. Exercises that worsen pain or swelling require review; an article cannot prescribe the right loading progression. Longer-term care may address stiffness, muscle weakness and the practical tasks the person wants to regain, with pain management and other professionals involved when needed. Pain intensity, swelling and ability to perform ordinary movements provide different information. Recovery should be judged across those features rather than by the disappearance of visible bruising alone. ²⁵

Surgery needs a separate hemostatic plan

Before surgery or an invasive procedure, the treating teams need a written plan based on the confirmed diagnosis, inhibitor history and current preventive medicine. They must know which laboratory assays are suitable, which treatments are available and how bleeding control will be assessed during and after the procedure. Routine prophylaxis does not automatically provide all the cover needed for an operation. Other medicines and health conditions can also change the balance between bleeding and clotting risks. ¹⁷

Planning continues beyond the operating room. The team considers postoperative monitoring, additional treatment, wound healing, mobility and rehabilitation, and who will manage any infusions after discharge. A satisfactory result immediately after surgery does not remove the need for later observation. Rehabilitation itself may need coordination with hemostatic treatment, because recovery involves movement and tissue healing beyond the day of surgery. ¹⁷

Before leaving hospital, the patient should understand the agreed treatment arrangements, warning symptoms and route for urgent help. Procedures at a different hospital may require advance coordination so the right expertise, product supply and laboratory support are actually available. ¹⁷

Dental care and medicines that preserve clots

Regular dental care and effective oral hygiene can reduce the need for more invasive treatment later. Bleeding gums should prompt dental assessment, rather than abandonment of brushing or an assumption that hemophilia explains every oral symptom. Gum disease and tooth problems can coexist with a bleeding disorder. Tell the dentist about the diagnosis and current treatment so prevention and any necessary intervention can be planned together with the hemophilia team. ¹⁴

An extraction, implant, gum surgery or certain deep local-anesthetic injections raises different bleeding questions from a routine examination. The required support depends on the actual procedure and the individual’s hemostatic situation. Contact the team before the intervention, rather than waiting to see whether prolonged bleeding develops afterward. The dental and hematology plans should fit together, including what to do if bleeding recurs at home. Do not assume that a previous uncomplicated cleaning proves a later extraction needs no special preparation. The team can explain whether local measures, clot-preserving treatment or additional hemostatic support belongs in that particular dental plan. ¹⁴

Antifibrinolytic medicines help preserve a clot by slowing its breakdown. They may be useful in selected dental or other bleeding situations, sometimes alongside treatment that improves clot formation. This is a different job from supplying factor VIII. Suitability depends on the bleeding site and the other medicines being used, so a plan for mouth bleeding should not be applied automatically to blood in the urine or an internal bleed. Ask the team which situations the prescription is intended to cover. ¹⁹

What long-term clinical follow-up should assess

A comprehensive review should look beyond the number of infusions or injections received. Bleed history, joint symptoms and physical assessment help show whether the current approach is protecting health and function. Bring up episodes that were uncertain as well as clearly treated bleeds, because recurring discomfort or reduced movement may deserve investigation. Follow-up also provides a chance to assess new evidence and treatment options against the person’s actual experience rather than choosing a medicine from a headline. Comparing function over time can reveal a change that a treatment calendar alone would miss. ²⁴

For people using home treatment, competence is something to maintain, not a box checked once. Refresher teaching can revisit early bleed recognition, sterile technique and when to call for help. Changes in dexterity, confidence or caregiver support can affect safe administration. Discuss missed or difficult treatments without hiding the problem; the team needs an accurate picture to understand whether inadequate protection reflects the treatment itself, difficulties delivering it or another issue requiring investigation. ²⁴

Review prescription medicines, nonprescription pain remedies and supplements with the team because they can affect bleeding risk or treatment decisions. Do not stop a prescribed medicine independently. Physical activity choices should account for joint condition and the treatment plan, supporting participation without treating every activity as equally suitable. Emotional strain and the demands of long-term care also deserve attention; counseling or other support can be part of maintaining health, alongside the hemostatic treatment itself. ¹⁹

Gene therapy: approval history and current access

BioMarin states that Roctavian was withdrawn from the market effective 29 May 2026. Its announcement attributes the decision to commercial considerations, not efficacy or safety, and supports continued monitoring of previously treated people. This market-status statement should not be confused with withdrawal of every jurisdiction’s authorization. ²⁶

Roctavian’s regulatory history concerns gene therapy intended to enable liver cells to produce factor VIII in selected adults. Eligibility assessment, liver-related precautions and long-term monitoring remain important. An older approval page does not demonstrate current access, and treatment should not be described as a guaranteed lifelong cure. Someone already treated still needs specialist follow-up; the commercial decision does not erase those clinical responsibilities or establish an individual’s continuing level of protection. The duration and magnitude of factor production vary; continuing measurements and clinical review remain necessary rather than assuming a stable result forever. ⁵

Acquired hemophilia A is a separate condition

Acquired hemophilia A develops when autoantibodies interfere with the person’s own factor VIII. It is different from inherited F8-related disease and from an inhibitor arising in someone treated for congenital hemophilia. New, unexplained bleeding in a person without a prior bleeding history can be a warning sign. Extensive skin, soft-tissue or muscle bleeding is important; the joint-bleeding pattern associated with congenital severe hemophilia is less typical. Investigation is needed rather than assuming all factor VIII problems share the same cause. Acquired disease does not follow the usual family transmission pattern of congenital hemophilia A. ¹¹

Specialist care addresses immediate bleeding control and the underlying inhibitor as separate priorities. Treatment choices depend on the clinical situation and cannot be borrowed from the congenital hemophilia overview in this article. A first diagnosis in adulthood does not establish acquired disease, because mild inherited hemophilia can also be recognized late. The history, factor testing and appropriate inhibitor investigations distinguish these possibilities. Significant new bleeding requires prompt assessment even when the person has never previously been told they have a bleeding disorder. ¹¹

Making care work outside the clinic

Keep emergency information that names hemophilia A, current treatment, inhibitor status and the treatment center’s contact details. Discuss what school staff or other caregivers need to know and how they should obtain help. The information should be usable by someone unfamiliar with the condition. Ask the care team about support for education, daily participation and the practical pressures on the family; the services available will depend on the center and local system. ²⁷

As children grow, responsibility can be transferred gradually through skills such as describing symptoms, knowing the treatment name and communicating with clinicians. Moving to adult care is more manageable when those skills develop over time rather than being expected all at once. Adults may also need renewed support when circumstances change. Identify who can help with treatment arrangements and continuity, especially when a familiar caregiver is no longer available. ²⁷